Shivani Chandrashekhar Bedarkar
Avishkar Hanamantrao Agarkhed
- Research Scholar, Department of Pharmacology, Student of ASPM’s KT Patil College of Pharmacy, Siddharth Nagar, Barshi Road, Osmanabad, Maharashtra, India
- Research Scholar, Department of Pharmacology, Student of ASPM’s KT Patil College of Pharmacy, Siddharth Nagar, Barshi Road, Osmanabad, Maharashtra, India
Abstract
Even in situations where it wasn’t necessary, antivenom research was applied to snake bite cases. In order to improve their level of understanding, primary practitioners should receive training on handling envenomation situations as well as current recommendations and references. In cases of snake bites, antivenom must be delivered according to applicable systemic and original indications.More than ten percent of cases with admitted ASV experience some sort of reaction, ranging from a minor urticarial rash to a serious anaphylactic reaction. While antivenoms are the first line of treatment in situations of life-threatening envenomation, especially snake sucks, they also result in serious adverse medication reactions.
Asia is home to many different species of snakes, and one of the biggest health risks is hemotoxic snake envenomation. Because of resource limitations, the standard diagnostic procedure calls for a 20-minute whole blood clotting time (20WBCT). Antisnake venom (ASV) must be administered in cases of systemic envenomation, which is characterized by bleeding problems or an extended clotting time. This case report describes a patient who needed two doses of ASV at first, but whose clotting time eventually recovered to normal.
The case report that is being presented highlights even more the variation in the way that patients react to antivenom, illuminating the complexities of treatment and the need for close observation. The goal of this all-inclusive strategy is to improve practitioners’ proficiency in handling cases of snake envenomation, reducing risks, and improving patient outcomes.
Keywords: Snakebite; Envenoming; Antivenom; Elixir responses; Anaphylaxis.
[This article belongs to International Journal of Toxins and Toxics(ijtt)]
Browse Figures
References
1. Habib AG. Effect of pre-medication on early adverse reactions following antivenom use in snakebite: a systematic review and meta-analysis. Drug safety. 2011 Oct;34:869–80.
2. Moran NF, Newman WJ, Theakston RD, Warrell DA, Wilkinson D. High incidence of early anaphylactoid reaction to SAIMR polyvalent snake antivenom. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1998 Jan 1;92(1):69–70.
3. Malasit P, Warrell DA, Chanthavanich P, Viravan C, Mongkolsapaya J, Singhthong B, Supich C. Prediction, prevention, and mechanism of early (anaphylactic) antivenom reactions in victims of snake bites. British medical journal (Clinical research ed.). 1986 Jan 1;292(6512):17.
4. de Silva HA, Pathmeswaran A, Ranasinha CD, Jayamanne S, Samarakoon SB, Hittharage A, Kalupahana R, Ratnatilaka GA, Uluwatthage W, Aronson JK, Armitage JM. Low-dose adrenaline, promethazine, and hydrocortisone in the prevention of acute adverse reactions to antivenom following snakebite: a randomised, double-blind, placebo-controlled trial. PLoS medicine. 2011 May 10;8(5):e1000435.
5. León G, Herrera M, Segura Á, Villalta M, Vargas M, Gutiérrez JM. Pathogenic mechanisms underlying adverse reactions induced by intravenous administration of snake antivenoms. Toxicon. 2013 Dec 15;76:63–76.
6. Warrell DA. Epidemiology of snake-bite in South-East Asia region. Guidelines for the management of snakebite. New Delhi: WHO regional office for Southeast Asia. 2010:35–45.
7. Gawarammana IB, Kularatne SA, Kumarasiri RP, Senanayake N, Dissanayake WP, Ariyasena H. Parallel infusion of hydrocortisone±chlorpheniramine bolus injection to prevent acute adverse reactions to antivenom for snakebites. Medical Journal of Australia. 2004 Jan;180(1):20–3.
8. Simons FE, Gu X, Simons KJ. Epinephrine absorption in adults: intramuscular versus subcutaneous injection. Journal of allergy and clinical immunology. 2001 Nov 1;108(5):871–3.
9. Rawas-Qalaji MM, Simons FE, Simons KJ. Sublingual epinephrine tablets versus intramuscular injection of epinephrine: dose equivalence for potential treatment of anaphylaxis. Journal of allergy and clinical immunology. 2006 Feb 1;117(2):398–403.
10. Lieberman P. Use of epinephrine in the treatment of anaphylaxis. Current opinion in allergy and clinical immunology. 2003 Aug 1;3(4):313–8.
| Volume | 01 |
| Issue | 02 |
| Received | February 9, 2024 |
| Accepted | February 21, 2024 |
| Published | March 2, 2024 |